指南与共识复苏、休克与脓毒症重症综合管理与镇静镇痛

延长输注β-内酰胺类抗生素国际共识推荐:由美国临床药学学院、英国抗菌化学治疗学会、囊性纤维化基金会、欧洲临床微生物学与感染病学会、美国感染病学会、美国重症医学会及感染病药师学会共同认可

International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Di
指南 / 共识 · Pharmacotherapy · 2023-01-01
一句话结论国际专家组就β-内酰胺类延长输注的药代动力学与药效学目标、治疗药物监测及在重症与非重症成人、儿童和肥胖患者中的应用达成共识推荐。

该共识由临床药学与医学国际专家组制定,针对静脉β-内酰胺类抗生素延长输注(含延长和持续输注)给出治疗推荐。β-内酰胺类呈时间依赖性杀菌活性,疗效与给药间期内游离药物浓度高于病原体最低抑菌浓度(MIC)的时间直接相关,延长输注可增加高于MIC的时间。共识涵盖药代动力学与药效学目标、治疗药物监测考虑,以及重症与非重症成人、儿童和肥胖患者的延长输注应用。推荐经ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP审阅并认可。

要点

  • β-内酰胺类为时间依赖性杀菌剂,细菌负荷下降与给药间期内游离药物浓度高于MIC的时间直接相关。
  • 延长输注(含延长输注和持续输注)用于静脉β-内酰胺类给药,以增加高于MIC的时间。
  • 共识就药代动力学与药效学目标、治疗药物监测考虑给出推荐。
  • 推荐覆盖重症与非重症成人患者、儿童患者和肥胖患者。
  • 延长输注方案已在世界范围内实施,但实施情况不一致。

适用人群与场景

  • 重症成人患者
  • 非重症成人患者
  • 儿童患者
  • 肥胖患者

研究设计与关键结果

  • 共识由临床药学与医学专家组成的国际专家组制定,就β-内酰胺类延长输注给出治疗推荐。
  • 推荐内容包括药代动力学与药效学目标、治疗药物监测考虑,以及重症与非重症成人、儿童和肥胖患者的延长输注应用。
  • 该推荐经美国临床药学学院(ACCP)、英国抗菌化学治疗学会(BSAC)、囊性纤维化基金会(CFF)、欧洲临床微生物学与感染病学会(ESCMID)、美国感染病学会(IDSA)、美国重症医学会(SCCM)和感染病药师学会(SIDP)审阅并认可。

证据类型、等级与局限

  • 证据类型:国际专家共识指南。
  • 推荐由ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP审阅并认可。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 原文未据此给出推荐

指南或共识出处

  • 延长输注β-内酰胺类抗生素使用国际共识推荐(International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics),由ACCP、BSAC、CFF、ESCMID、IDSA、SCCM和SIDP认可。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Intravenous β-lactam antibiotics remain a cornerstone in the management of bacterial infections due to their broad spectrum of activity and excellent tolerability. β-lactams are well established to display time-dependent bactericidal activity, where reductions in bacterial burden are directly associated with the time that free drug concentrations remain above the minimum inhibitory concentration (MIC) of the pathogen during the dosing interval. In an effort to take advantage of these bactericidal characteristics, prolonged (extended and continuous) infusions (PI) can be applied during the administration of intravenous β-lactams to increase time above the MIC. PI dosing regimens have been implemented worldwide, but implementation is inconsistent. We report consensus therapeutic recommendations for the use of β-lactam PI developed by an expert international panel with representation from clinical pharmacy and medicine. This consensus guideline provides recommendations regarding pharmacokinetic and pharmacodynamic targets, therapeutic drug monitoring considerations, and the use of PI β-lactam therapy in the following patient populations: severely ill and nonseverely ill adult patients, pediatric patients, and obese patients. These recommendations provide the first consensus guidance for the use of β-lactam therapy administered as PIs and have been reviewed and endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of America (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists (SIDP).

来源:Pharmacotherapy,查看原文。版权归原作者所有。

参考来源

  1. Hong LT, Downes KJ, FakhriRavari A, et al. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists: An executive summary. Pharmacotherapy. 2023. PMID: 37615244. doi:10.1002/phar.2844

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。